InvestorsHub Logo
icon url

Swampdude

10/20/19 8:40 AM

#339 RE: tdeck #337

Good morning t deck,

Once again your extensive DD and research have shined a very bright light on the potential for the progress of FOMX and it's FDA approved product and products still coming.

The coming months as well as the entire next year for FOMX hold enormous potential and will be very exciting to participate in.

Your in depth research will quiet the shorts (in here at least) and help the investor make informed decisions. Thank you yet again, you are appreciated.

SD
icon url

pete807

10/20/19 8:46 AM

#340 RE: tdeck #337

Joe Edelman increased his shares from 7 to 18% recently and he is the guru of biotech stocks.
icon url

Rookie2019

10/20/19 9:15 AM

#342 RE: tdeck #337

Nice insight here on FOMX Tdeck. As someone who also will be riding this company through the long list of catalysts, to say that the who's who of large shareholders especially Edelman at 18% is encouraging is an understatement of the year.

I plan to hang in for the ride, maybe sell some pieces along the way to recap some investment dollars. But otherwise off to the races.

Good luck to all longs and thank you again Tdeck for the continued hard work and well supported input.
icon url

harkmi

10/20/19 9:55 AM

#343 RE: tdeck #337

Again, near amazing insight and clarity on the 'time and tides' rise and fall of an investor's outlook on the FOMX landscape and timeline as we go forward.

For me, initially, it looks confusing, but having been around for one or two others the catalysts mentioned are there and the timing will prove out. The key is patience and observation.
tdeck, thanks for the steps and signposts provided. I have an initial position snd look forward to adding on dips that have 'opportunity' written all over them.
GLTA!
icon url

overmann333

10/20/19 11:26 AM

#345 RE: tdeck #337

Excellent post on FOMX Tdeck, much appreciated, I especially enjoyed the read on investor vs the others.

I am impressed with Foamix and them taking all the proper steps before approval to get this ready for sales and in offices. They are ready to rock.

This is going to be huge with gen z and millenials and once the word is out about how FMX101 performs there is going to be no stopping it.

icon url

JohnSamuel

10/20/19 1:31 PM

#349 RE: tdeck #337

You have done it again tdeck ... great detail for everyone to absorb and to continue learning about another great opportunity ...
As always, appreciate all your DD and all your insight.
Joe Edelman's position says a great deal because he loves to find these nuggets and expand his position as he becomes more and more confident in them and he obviously believes Foamix is one of them.

This is from an article about him from 2013 ... "BACKED BY SIX pharmaceutical-industry analysts, the 58-year-old Edelman is known for selecting the right products. "The critical thing we are doing is evaluating the science and the data to decide whether a drug will work and whether it will be approved," says Edelman, adding that he focuses mostly on early clinical information. "If we think there is a higher probability that a drug will work than the Street does, we may have a long on that position."

THANKS again for sharing tdeck ! ... ;)


John